You will be redirected to the website of our parent company, Schönherr Rechtsanwälte GmbH: www.schoenherr.eu
Our Healthcare & Life Sciences team provides fully integrated legal advice across one of the most highly regulated and rapidly evolving industries. We combine deep, industry-specific regulatory expertise with comprehensive transactional, financing, dispute resolution, IP and compliance capabilities.
With offices across Central Eastern Europe, we advise clients on both complex domestic and multi-jurisdictional matters, seamlessly coordinating cross-border projects across the region.
We advise all key stakeholders active in these industries, including manufacturers, distributors and operators, hospitals, physicians, insurers and other healthcare and care institutions, as well as enterprises ranging from innovative start ups to established multinational corporations and strategic and financial investors.
Our core strengths lie in life sciences regulatory advice and transactional work, in particular M&A, VC/PE and spin-off transactions, capital markets transactions (including IPOs), and financing. As a full-service law firm, we support clients throughout the entire business and product life cycle – from early-stage innovation and investment to market expansion and mature international operations.
Our Healthcare & Life Sciences practice is structured around the needs of the industry. We bring together regulatory, transactional, corporate, IP and dispute resolution expertise to deliver practical, strategic and commercially driven advice in regulated environments.
We provide regulatory advice across the full spectrum of healthcare and life sciences products, including pharmaceuticals, medical devices, biotechnology, digital health, food and feed, seeds, chemicals, cosmetics and select consumer goods.
We provide comprehensive transactional and corporate advice for clients across the healthcare and life sciences value chain – from innovative start-ups and emerging growth companies to established multinational corporations – including regulated product manufacturers, healthcare providers, insurers, management teams and strategic and financial investors, as well as issuers and underwriters in capital markets transactions.
In addition, we provide full transactional support, from due diligence and deal structuring to closing and post-closing integration.
We provide advisory services for hospitals, outpatient clinics, physician centres, nursing and care facilities, and other healthcare providers, covering regulatory, corporate, transactional and contentious matters across the full spectrum of healthcare delivery.
In addition, we provide representation before national and European authorities and courts, including medical malpractice and professional liability claims.
We advice on the drafting, negotiation and implementation of sector-specific agreements across the healthcare and life sciences value chain, including complex cross-border contractual frameworks and long-term strategic partnerships.
In addition to our core regulatory and transactional practice, our clients benefit from seamless access to Schoenherr's dedicated specialists across a broad range of complementary practice areas essential to the healthcare and life sciences industries. These experts collaborate closely with our Healthcare & Life Sciences team to deliver comprehensive and fully integrated legal advice.
25 June 2026
R.Bicek E.Buriánek O.Fiala A.Glos M.Gremillot N.Hrubá Š.Kopárek A.Kučerová J.Kupčík K.Lehečková A.Procházka M.Petr M.Voldánová
CZ: Schoenherr Journal Edition 20
The Schoenherr Journal, published by Schoenherr's Prague office, looks at significant new legal developments in the Czech Republic.
Poland: Schoenherr advises mBank on financing of Bold Capital's investment in Primus clinic network
Schoenherr advised mBank on the financing of Bold Capital's investment in Primus, a network of outpatient clinics in Poland. The transaction, structured as a search fund model, marks a significant investment in the Polish healthcare sector and sets the stage for further consolidation of the primary care market in Silesia.
02 April 2026
austria bulgaria czech republic romania serbia
S.Rosenthaler A.Natterer N.Kerschbaumer D.Birnbauer S.Sayahpour E.Todorova A.Minioti H.Hadzhiiliev M.Demirev K.Gabryjańczyk O.Grecu I.Sava M.Voldánová K.Lehečková
to the point: Healthcare & Life Sciences Q1/2026
Welcome to the new edition of to the point: Healthcare & Life Sciences – a format designed to keep you informed about legal and regulatory developments shaping the sector across Europe.
Event Review | Healthcare & Life Sciences | Masterclass & Investor's Lounge
10 March 2026 | Vienna | Schoenherr × invest.austria
Austria/Belgium: Schoenherr advises FRI-Invest GmbH and its shareholders on Fluidda's acquisition by Banook
Schoenherr advised FRI-Invest GmbH and its shareholders on the transaction structure and Austrian law aspects of Fluidda's acquisition by Banook. Previously, Schoenherr had also advised FRI-Invest GmbH on its initial investment in Fluidda.
Telemedicine on the rise in Austria?
Seven out of the 328 pages of the new green/conservative government's programme are dedicated to the health sector. One bullet point on this programme for the next five years is to implement telemedicine treatment in the best possible way. The government further explains that it aims to promote digitalisation in diagnosis, treatment and medical research and thus strengthen Austria as a health hub.
find all healthcare & life sciences news here